
GLP-1 obesity drugs offer early hope for PMOS, a hormonal disorder
GLP-1 obesity medications, including semaglutide, are showing early promise in treating PMOS by promoting weight loss, improving insulin resistance, and balancing hormones to support ovulation. Small studies led by Dr. Melanie Cree, including a Colorado patient who saw slowed hair growth, normalized periods, and significant weight loss, suggest potential benefits for PMOS patients. However, insurance coverage remains a major hurdle since PMOS is not an approved indication for these drugs and results vary, highlighting the need for more research and access solutions.


